Chlorambucil/ XXXX vs. @entity3726 in symptomatic low-grade @entity1893 : a randomized trial from the Lymphoma Group of Central Sweden.

@entity1 @entity229 @entity3726 @entity10094 @entity1072 @entity5805 @entity1893
Two hundred fifty-nine previously untreated @entity1 with low-grade @entity1893 ( @entity1893 ), Ann Arbor stages III and IV, entered a randomized multicenter trial comparing the therapeutic effect of @entity5805 / @entity229 (ChP) vs. @entity3726 . All @entity1 had symptomatic disease. The therapeutic aim was to achieve an asymptomatic state in the ChP group (n = 132), while in @entity3726 -treated @entity1 (n = 127) the intention was to reach a complete remission (CR). The response rate (CR+PR at 8 months) was 36% in the ChP and 60% in the @entity3726 group (p < 0.01). Three and 5-year survival rates were 59% and 41% in the ChP group and 64% and 44% in the @entity3726 group. The corresponding median survival times were 46 and 52 months. After correction for intercurrent deaths, the overall 5-year survival was 49% for ChP and 54% for @entity3726 -treated @entity1 . The differences were statistically not significant. The time from diagnosis to randomization (time with @entity10094 ) was longer than one year in half of the @entity1 . The median survival time from diagnosis was 68 months, with no differences between the treatment groups. In all histological subgroups ( @entity1072 , IC, CC, and CB-CC), a higher remission rate was seen with the @entity3726 regimen but with no statistically significant influence on survival. Comparing @entity1 below and above 65 years of age, no significant difference in survival was noted between the two treatment groups. The results do not support the use of intensive chemotherapy as first-line therapy in symptomatic low-grade @entity1893 .
